Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab (F520) plus lenvatinib vs lenvatinib in first-line hepatocellular carcinoma
CTR20221626Phase 3Terminated
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rulonilimab in hepatocellular carcinoma (HCC), sponsored by Shandong New Era Pharmaceutical. Started Jul 2022; status: terminated.
02
Drugs
rulonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221626.